Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are important immune checkpoint molecules, and blocking PD-1/PD-L1 reduces the tumor burden and indicate promising outcomes in many tumor types [16,17]. This evidence concerns the gene CD274 and neoplasm.